Wedbush Raises Earnings Estimates for Blueprint Medicines

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at Wedbush upped their FY2026 earnings per share estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Wednesday, October 30th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings of $2.05 per share for the year, up from their prior forecast of $1.84. The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.99) per share. Wedbush also issued estimates for Blueprint Medicines' FY2027 earnings at $7.29 EPS.

Other equities research analysts have also recently issued reports about the stock. UBS Group assumed coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective for the company. Robert W. Baird increased their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Needham & Company LLC reissued a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research note on Wednesday. Barclays upped their target price on Blueprint Medicines from $75.00 to $105.00 and gave the stock an "equal weight" rating in a research report on Monday, July 29th. Finally, Morgan Stanley lifted their price target on shares of Blueprint Medicines from $110.00 to $115.00 and gave the company an "equal weight" rating in a research report on Friday, July 12th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus price target of $120.39.

Blueprint Medicines Stock Down 1.2 %

BPMC stock traded down $1.05 during trading hours on Thursday, hitting $88.19. The company's stock had a trading volume of 527,476 shares, compared to its average volume of 693,044. The company has a market capitalization of $5.52 billion, a PE ratio of -18.43 and a beta of 0.58. The stock has a 50 day moving average price of $88.98 and a two-hundred day moving average price of $98.43. The company has a quick ratio of 3.65, a current ratio of 3.71 and a debt-to-equity ratio of 1.06. Blueprint Medicines has a 12 month low of $53.73 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The firm's revenue was up 126.5% on a year-over-year basis. During the same period in the previous year, the company earned ($2.20) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BPMC. Allspring Global Investments Holdings LLC bought a new stake in shares of Blueprint Medicines during the first quarter worth $218,000. Principal Financial Group Inc. grew its position in shares of Blueprint Medicines by 331.9% during the 1st quarter. Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company's stock worth $5,945,000 after buying an additional 48,160 shares during the period. SG Americas Securities LLC raised its stake in shares of Blueprint Medicines by 117.6% during the first quarter. SG Americas Securities LLC now owns 11,865 shares of the biotechnology company's stock worth $1,126,000 after buying an additional 6,412 shares during the last quarter. Swiss National Bank lifted its holdings in Blueprint Medicines by 0.4% in the first quarter. Swiss National Bank now owns 114,000 shares of the biotechnology company's stock valued at $10,814,000 after buying an additional 500 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in Blueprint Medicines in the first quarter valued at approximately $474,000.

Insider Buying and Selling

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the company's stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the sale, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the business's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares of the company's stock, valued at approximately $3,236,395.51. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Fouad Namouni sold 3,633 shares of the company's stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.